The heterogeneity of breast cancer, with various subtypes such as triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer, further complicates therapeutic approaches [3,4]. The gene discussed is ERBB2; the disease is breast carcinoma.